The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years.
Keystone
The pharmaceutical giant Novartis has announced plans to invest CHF90 million ($91.5 million) over three years on a production site for cell and gene therapies. The goal is to enable new treatments to be delivered in Europe.
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time that it wanted to create 350 new positions, mainly in its biotech business.
The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years, Novartis said in a statement on Monday.
“This investment illustrates the changes the sector is undergoing,” said Matthias Leuenberger, Head of Switzerland at Novartis. “As we invest in new highly specialised technologies, the importance of some traditional areas will diminish,” he said.
The announcement of the investment in Stein comes after the European Commission approved the company’s Kymriah cell therapyExternal link for the treatment of acute B-cell lymphoblastic leukemia in children and young adults up to 25 years.
Novartis already operates a plant in the US in Morris Plains, New Jersey, that specialises in the production of cell and gene therapies.
More
More
Novartis to shed 500 jobs in Basel
This content was published on
The Swiss pharmaceutical giant Novartis has announced that it plans to cut 500 jobs at its Basel headquarters in Switzerland over the next 18 months.
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
Experts lower Swiss growth forecasts due to US trade tensions
This content was published on
The uncertainty caused by ongoing trade conflicts is making companies hesitant to make decisions, which significantly hinders investment.
Swiss abbot resumes role following abuse investigation
This content was published on
Scarcella was accused in the Catholic Church abuse scandal last autumn. In October 2024, the Vatican declared there was no evidence of abuse or harassment against him.
Swiss stock exchange operator SIX to cut 150 jobs in efficiency drive
This content was published on
"We're not revealing the number of job losses at each location at the moment," said a SIX spokesperson. However, there will be cuts in Switzerland as well.
Martin Pfister named new Swiss government minister
This content was published on
Pfister’s election keeps the linguistic balance of Switzerland’s government, but shifts gender balance to only two women.
Swiss interior minister meets UN leaders in New York for women’s rights session
This content was published on
The Swiss interior minister also held bilateral meetings with UN Secretary-General António Guterres and Sima Sami Bahous, Executive Director of UN Women
The image of foreigners in Switzerland has deteriorated
This content was published on
The Federal Statistical Office has found that Swiss people’s views of foreigners have worsened over the last couple of years.
After mild winter, nature wakes up earlier in Switzerland
This content was published on
Once again this year, nature has woken up earlier than normal, between a week and ten days ahead of schedule due to a mild winter.
Computer failure disrupts air traffic at Geneva airport
This content was published on
A computer breakdown has disrupted operations at Geneva Airport since midday on Tuesday. Significant delays are expected.
Swiss show high willingness to pay for sustainable flats
This content was published on
Tenants in Switzerland are in favour of sustainable flats. However, the willingness to pay differs by income according to a new study.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
This content was published on
The status of Novartis as a leading Big Pharma company is beyond doubt. But after five difficult years, critical choices about assets are looming.
Swiss pharma suspected of delaying generic competition
This content was published on
The United States Food and Drug Administration (FDA) lists Novartis and Roche among drug-makers suspected of hindering generic competition.
Export growth increasingly depends on pharmaceuticals
This content was published on
Swiss exports hit a record CHF210 billion ($211 billion) last year and the pharmaceutical sector was one of the big drivers.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.